Skip to main content
Premium Trial:

Request an Annual Quote

Clinical Reference Lab to Validate Nuclea's Assays

NEW YORK (GenomeWeb) – Nuclea Biotechnologies today said it has inked an agreement with Clinical Reference Laboratory to validate three of Nuclea's tests.

As part of the deal, CRL will initially validate Nuclea's Oncogene Science 159 gene-based prostate cancer monitoring test. Nuclea obtained the test when it acquired Wilex, the wholly owned subsidiary of Wilex AG, in September.

CRL will also validate Nuclea's Nuvera breast cancer assay and its US Food and Drug Administration-approved, serum HER-2/neu blood test.

Nuclea will clinically interpret test results and market and distribute the tests. The Pittsfield, Mass.-based company said that it anticipates the Nuvera and Oncogene Science assays to be available in the next 60 days, while the HER-2/neu assay will be launched later this year.

Financial and other terms of the deal were not disclosed.

The Scan

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.

Family Genetic Risk Score Linked to Diagnostic Trajectory in Psychiatric Disorders

Researchers in JAMA Psychiatry find ties between high or low family genetic risk scores and diagnostic stability or change in four major psychiatric disorders over time.

Study Questions Existence of Fetal Microbiome

A study appearing in Nature this week suggests that the reported fetal microbiome might be the result of sample contamination.

Fruit Fly Study Explores Gut Microbiome Effects on Circadian Rhythm

With gut microbiome and gene expression experiments, researchers in PNAS see signs that the microbiome contributes to circadian rhythm synchronicity and stability in fruit flies.